DENTSPLY SIRONA (NASDAQ:XRAY) Stock Rating Upgraded by Citigroup

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by Citigroup to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities analysts also recently commented on the company. Wells Fargo & Company boosted their price objective on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Robert W. Baird boosted their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. UBS Group lowered their price objective on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Finally, Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $14.08.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $12.51 on Wednesday. The company has a market capitalization of $2.50 billion, a PE ratio of -4.16, a price-to-earnings-growth ratio of 1.42 and a beta of 0.99. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The business’s fifty day moving average is $12.37 and its 200 day moving average is $12.07. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. During the same quarter last year, the firm posted $0.26 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Insider Activity

In related news, Director Gregory T. Lucier acquired 15,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $12.45 per share, with a total value of $186,750.00. Following the completion of the purchase, the director directly owned 65,000 shares of the company’s stock, valued at $809,250. The trade was a 30.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James D. Forbes acquired 5,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 70,000 shares of company stock worth $956,437 over the last ninety days. Insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several large investors have recently added to or reduced their stakes in XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA during the first quarter worth approximately $26,000. Goldman Sachs Group Inc. increased its stake in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC increased its stake in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after acquiring an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in DENTSPLY SIRONA by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after acquiring an additional 41,579 shares during the last quarter. Finally, Focus Partners Wealth increased its stake in DENTSPLY SIRONA by 59.1% during the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after acquiring an additional 9,355 shares during the last quarter. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.